January 2025 Revolutionizing Immunology: Oral Drugs with Biologics-Like Efficacy Science-driven clinical stage organization with industry-leading oral immunology pipeline J.P. Morgan Healthcare Conference Nello Mainolfi, Ph.D., Founder, President and CEO Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. These statements include, but are not limited to, implied and expr ...

4Q and FY 2018 Earnings • February 21, 2019 CAESARS ENTERTAINMENT CORPORATION 1 Forward Looking Statements Certain information in this presentation and discussed on the conference call which this presentation accompanies constitutes forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the fact that they do not relate strictly to historical or current facts and by the use of words such as "will," "may," "expect," "project ...

ENTERTAINMENT 1Q 2019 Earnings • May 1, 2019 CAESARS ENTERTAINMENT CORPORATION D Forward Looking Statements Certain information in this presentation and discussed on the conference call which this presentation accompanies constitutes forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the fact that they do not relate strictly to historical or current facts and by the use of words such as "will," "may," "expect," "projec ...

Financial Performance - Caesars Entertainment announced a merger with Eldorado Resorts on June 24, 2019, creating the largest owner and operator of U S gaming assets[5] - Net revenues increased by 4 9% year-over-year, but decreased by 1 2% excluding Centaur[6] - Adjusted EBITDAR increased by 1 3% year-over-year, but decreased by 5 1% excluding Centaur[6] - The adjusted EBITDAR margin was 28 4%[6] Regional Performance - Las Vegas net revenues increased by 1 0% year-over-year to $1 002 million[11] - Las Vegas adjusted EBITDAR increased by 1 6% year-over-year to $389 million, with a margin of 38 8%, up 20 bps[11] - Other U S net revenues increased by 8 4% year-over-year to $1 064 million[11] - Other U S adjusted EBITDAR increased by 4 7% year-over-year to $270 million, but the margin decreased by 90 bps to 25 4%[11] - "All Other" region reported a $28 million adjusted EBITDAR loss, a decrease of $10 million year-over-year[11] Las Vegas Strip Key Performance Indicators - Occupancy increased by 370 bps[9] - ADR (Average Daily Rate) increased by 2 2%[9] - RevPAR (Revenue Per Available Room) increased by 6 2%[9] - Adjusted EBITDAR increased by 1 6%[9] - Adjusted EBITDAR Margin increased by 20 bps[9] Capital Expenditures and Debt - Total financial debt (excluding convertible debt) was $7 861 billion, with 60% fixed and 40% variable[30] - Total financial debt plus REIT capitalized leases was $14 085 billion[30] - The company estimates 2019 maintenance capex to be between $375 million and $450 million, and development capex between $475 million and $550 million[35]

Corporate Presentation NOVEMBER 18, 2024 FORWARD-LOOKING STATEMENTS This Operating and Financial Data should be read in connection with our Quarterly Report on Form 10-Q for the quarter ended September 30, 2024. Statements made in this presentation may be forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Such for- ward-looking statements are intended to be covered by the safe harbor provisions for forward-looking statements contained in Section ...

Financial Performance - Net revenues increased by 2.3% year-over-year, reaching $2.236 billion[4] - Adjusted EBITDAR increased by 6.3% year-over-year[7] - Adjusted EBITDAR margin increased by 100 bps[7] - Las Vegas net revenues increased by 6.9% year-over-year, reaching $973 million[10] - Las Vegas Adjusted EBITDAR increased by 16.0% year-over-year, reaching $356 million[10] - Other U S net revenues decreased by 0.5% year-over-year, to $1.119 billion[10] - All Other net revenues decreased by 4.0% year-over-year, to $144 million[10] Key Performance Indicators - Customer Service Scores increased by 2.65%[7] - Net Promoter Score increased by 4.02%[7] - Las Vegas Occupancy increased by 290 bps[9] - Las Vegas ADR increased by 3.7%[9] - Las Vegas RevPAR increased by 7.0%[9] Efficiency - Labor efficiency improved by 20 bps[2] - Marketing efficiency improved by 60 bps[3] Merger - Merger with Eldorado Resorts expected to close in 1H 2020[8]

Financial Performance - Q4 2019 - Net revenues increased by 2.6% year-over-year[3], reaching $2169 million[8] - Adjusted EBITDAR increased by 3.4% year-over-year[3], with a margin of 27.0%, up 20 bps[3] - Las Vegas net revenue increased by 4.2% year-over-year[3], reaching $989 million[8] - Las Vegas adjusted EBITDAR increased by 3.4% year-over-year[3], reaching $363 million[8] - Adjusted EBITDAR excluding Rio increased by 4.5% year-over-year[3] Financial Performance - Full Year 2019 - Net revenues increased by 4.2% year-over-year[3], reaching $8742 million[16] - Adjusted EBITDAR increased by 4.7% year-over-year[3], with a margin of 27.6%, up 10 bps[3], reaching $2417 million[17] - Marketing efficiency improved to 20.0%, up 10 bps[3] - Labor efficiency improved to 23.4%, up 30 bps[3] Las Vegas Key Performance Indicators - Las Vegas RevPAR increased by 2.1% year-over-year[3] - Las Vegas Adjusted EBITDAR Margin was 36.7%[10]

Financial Performance - Q1 2020 - Net revenues for Caesars Entertainment were $1828 million, a decrease of $287 million or 136% year-over-year [6] - Adjusted EBITDAR was $302 million, a decrease of $260 million or 463% year-over-year [6] - Las Vegas net revenue was $822 million, down $133 million or 139% year-over-year [6] - Other U S net revenue was $874 million, down $136 million or 135% year-over-year [6] - All Other net revenue was $132 million, down $18 million or 120% year-over-year [6] Impact of COVID-19 - Temporary property closures began in March, impacting financial results [1] - Aggressive cost management was implemented to preserve liquidity [1] - The company provided two weeks of closure pay and continued medical benefits for employees [3] Liquidity and Debt - Cash and cash equivalents totaled $2677 million as of March 31, 2020 [14] - Total financial debt (excluding convertible debt) was $8700 million [14] - Maintenance Capex was $109 million [15]

Company Overview - Shattuck Labs is a clinical-stage biotechnology company focused on bi-functional fusion proteins [10] - The company has $114.6 million in cash and cash equivalents and investments as of March 31, 2024, expected to fund operations into 2026 [10] SL-172154 Clinical Trials (AML/HR-MDS) - In a Phase 1A/B trial, 14 frontline TP53m AML patients were enrolled [77] - In the same trial, 22 frontline HR-MDS patients were enrolled [77] - In TP53m AML patients, 3 out of 11 evaluable patients achieved a CR/CRi [54] - In HR-MDS patients, 9 out of 14 evaluable patients achieved a CR/mCR [70] - 81% of HR-MDS patients in the trial had TP53 mutation or deletion [65] SL-172154 Clinical Trials (PROC) - Enrollment was completed in Q4'23 in the Phase 1B dose expansion cohort for PROC [110] - Initial data showed a 27% Objective Response Rate (ORR) for SL-172154 in combination with PLD [110] - 50% of PROC patients had received one prior line of systemic therapy, and 50% had received two or more [106]

Company Overview - Precision Optics (POCI) is a vertically integrated optics company focused on micro-optics and imaging technologies for the healthcare and defense/aerospace industries[7] - The company's business model involves close collaboration with medical device and defense companies from the early design stages through manufacturing[13, 14] - The company has launched Unity CMOS Imaging Platform to drive growth in development pipeline[11] Financial Performance - The company's revenue has grown from $3.9 million in 2016 to $19.1 million in 2024[51] - The company's gross margin was 30.3% in 2024[54] - The company's adjusted EBITDA was -$1.55 million in 2024[57] Recent Orders and Backlog - The company announced a $9 million production order in May 2024 for a single-use cystoscopy program[47] - The company has minimum purchase commitments of nearly $4 million per year through calendar year 2026 for a top tier aerospace program[47] - The company's current customer program backlog is $6.6 million, expected to be delivered over the next 12 months (as of April 2025)[47] Growth Strategy - The company aims to continue and expand production lines for record backlog, especially for two recent large programs[48] - The company intends to advance pipeline projects to commercialization and expand the pipeline with new development programs leveraging the Unity Platform[48]